Statement of Changes in Beneficial Ownership (4)
December 06 2022 - 06:52PM
Edgar (US Regulatory)
|
FORM 4
[ ] Check this box if no longer subject to Section
16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person * Singer Nicholas
Jason |
2. Issuer Name and Ticker or Trading
Symbol Eterna Therapeutics Inc. [ ERNA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
_____ Officer (give title
below) _____ Other
(specify below)
|
|
(Last)
(First)
(Middle)
C/O ETERNA THERAPEUTICS INC., 10355 SCIENCE CENTER DRIVE,
SUITE 150 |
3. Date of Earliest Transaction (MM/DD/YYYY)
12/2/2022
|
|
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
|
Common Stock |
12/2/2022 |
|
P |
|
70822 |
A |
$3.28 (1) |
121822 |
I |
By Purchase Capital LLC |
|
Common Stock |
12/2/2022 |
|
P |
|
212464 |
A |
$3.28 (1) |
266214 |
I |
By Pacific Premier Trust, Custodian, FBO Nicholas
J. Singer |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Warrants (right to buy) |
$3.28 (1) |
12/2/2022 |
|
P |
|
141644 |
|
6/2/2023 |
6/2/2028 |
Common Stock, par value $0.005 per
share |
141644 |
$0.125 (1) |
141644 |
I |
By Purchase Capital LLC |
|
Warrants (right to buy) |
$3.28 (1) |
12/2/2022 |
|
P |
|
424928 |
|
6/2/2023 |
6/2/2028 |
Common Stock, par value $0.005 per
share |
424928 |
$0.125 (1) |
424928 |
I |
By Pacific Premier Trust, Custodian, FBO Nicholas
J. Singer |
| Explanation of
Responses: |
| (1) |
The reporting person entered
into a Securities Purchase Agreement with the Issuer on November
23, 2022, pursuant to which, on December 2, 2022, the reporting
person acquired an aggregate of 283,286 units for a purchase price
of $3.53 per unit, each unit consisting of one share of common
stock, par value $0.05 per share ("Common Stock"), and two
warrants, each exercisable to purchase one share of Common Stock at
an exercise price of $3.28 per share. The purchase price for each
unit included $0.125 for each warrant in accordance with Nasdaq
rules. |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
Singer Nicholas Jason
C/O ETERNA THERAPEUTICS INC.
10355 SCIENCE CENTER DRIVE, SUITE 150
SAN DIEGO, CA 92121 |
X |
|
|
|
Signatures
|
|
/s/ Nicholas J. Singer |
|
12/6/2022 |
| **Signature of Reporting
Person |
Date |
|
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
| * |
If the form is filed by more than one
reporting person, see Instruction 4(b)(v). |
| ** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
|
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to Jun 2023
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2022 to Jun 2023
